ADME profile of phencyclidine (PCP) analogues: emerging dissociative hallucinoge...

연구 요약

ADME profile of phencyclidine (PCP) analogues: emerging dissociative hallucinogens 3-MeO-PCP (CAS: 72242-03-6) and 4-MeO-PCP (CAS: 2201-35-6)-a multi-in silico approach for comprehensive prediction of absorption, distribution, metabolism and excretion relevant to clinical and forensic toxicology.

Archives of toxicology 학술지에 발표된 이 연구는 Jurowski K, Kobylarz D, Noga M 외 연구팀이 수행하였습니다.

이 연구는 'ADME profile of phencyclidine (PCP) analogues: emerging dissociative hallucinogens 3-MeO-PCP (CAS: 72242-03-6) and 4-MeO-PCP (CAS: 2201-35-6)-a multi-in silico approach for comprehensive prediction of absorption, distribution, metabolism and excretion relevant to clinical and forensic toxicology.'에 대한 과학적 분석을 제공합니다.

핵심 내용

A multi-platform in silico workflow was applied to characterize the ADME profile of the methoxy-substituted phencyclidines 3-MeO-PCP and 4-MeO-PCP for clinical toxicological and forensic use. Predictions from ACD/Percepta, SwissADME, pkCSM, ADMETlab 3.0, DruMAP 2.0 and XenoSite were triangulated under OECD (Q)SAR principles with explicit applicability-domain checks. Both analogues were predicted to exhibit high passive permeability, high gastrointestinal absorption, and blood-brain barrier access. Distribution outputs consistently indicated extensive tissue partitioning, high plasma protein binding (~ 70-80%), and large apparent volumes of distribution. Metabolic liability was assigned primarily to CYP3A4, CYP2D6 and CYP2C19, with early O-demethylation to phenolic metabolites followed by rapid glucuronidation; modelled CYP values support clinically relevant drug-drug interaction and genotype effects. XenoSite suggested a higher theoretical bioactivation propensity for 4-MeO-PCP via arene-oxide/quinone-methide manifolds. Excretion modules predicted renal transporter involvement, while total clearance and half-life estimates showed method-dependent dispersion. The consolidated profile supports targeted bioanalysis (phenolic O-glucuronides; adduct screening in severe cases), informs matrix selection and exposure back-extrapolation, and prioritizes validation studies (recombinant CYP phenotyping, transporter assays, protein/brain binding). The workflow generalizes to related dissociatives and provides a transparent, regulator-aligned template for rapid ADME risk triage when in vivo data are limited.

일반인을 위한 해석

구체적인 실천 사항은 담당 의사 또는 약사와 상담하시기 바랍니다.

실천 사항

• 현재 복용 중인 약물이나 영양제에 대해 궁금한 점이 있다면 담당 의사 또는 약사와 상담하시기 바랍니다
• 약물이나 영양제의 용법·용량을 임의로 변경하지 마세요
• 이상 반응이 나타나면 즉시 전문가에게 문의하세요

의사/약사의 전문적 판단을 대체하지 않습니다 (PMID: 41606395)

📄 [전문 보기 (Markdown)](fulltext/41606395-adme-profile-of-phencyclidine-pcp-analogues-emerging-dissoci.md)